Skip to main content

Table 2 Evaluation of pain control and postoperative recovery

From: RETRACTED ARTICLE: Efficacy of dexmedetomidine as an adjunct to ropivacaine in bilateral dual-transversus abdominis plane blocks in patients with ovarian cancer who underwent cytoreductive surgery

 

CON (n = 29)

TAP-R (n = 29)

TAP-DR (n = 30)

P-value

The first bolus time

3.0 (2.3–3.5)

7.3 (6.5–8.0)*

13.5 (12.4–14.5)*#

< .001

Sufentanil consumption(ug)

 Post-operative~ 24 h

55 ± 8.5

53 ± 6.3

48 ± 6.4*

.003

 Post-operative~ 48 h

105 ± 16

102 ± 12

95 ± 12*

.017

Request for rescue analgesia, n (%)

14 (48)

7 (24)

5 (17)*

.021

Functional recovery

 Time to stand (h)

20 (17–21)

17 (15–20)

17 (15–20)

.096

 Time to walk (h)

21 (18–22)

20 (17–23)

18 (16–20)

.146

 Time to return of bowel function (days)

3 (3–4)

3 (2–4)

3 (2–4)

.638

 Time to readiness for discharge (days)

10 (10–12)

10 (9–12)

10 (9–11)

.438

  1. The first bolus time and postoperative functional recovery are presented as median and interquartile range values
  2. Abbreviations: TAP-R Bd-TAP block with 0.3% ropivacaine, TAP-DR Bd-TAP block with 0.3% ropivacaine and 0.5 μg/kg of dexmedetomidine, CON Bd-TAP block with 0.9% normal saline
  3. *P < .05 vs. CON group; #P < .05 vs. TAP-R group